Affiliate Launch Planning: Pressure-Testing Launch Strategies through Interactive Workshop

Our client, a global pharmaceutical company, was planning to launch its first-ever biosimilar for the treatment of inflammatory conditions. It engaged Prescient to develop a more thorough understanding of the competitive landscape, refine its launch strategy and lay the groundwork for global and local biosimilar launches.

Positioning against the Competition: Developing a Message in a Crowded Market

Our client, a global pharmaceutical company, was planning to launch a second-in-class biologic in a crowded market space. However, the market was facing a potential game changer with the launch of an oral option that posed a threat to all biologic therapies. The client partnered with Prescient to maximize its market potential and optimize its positioning and messaging, both against same-class competitors and the soon-to-launch oral competitor.

Confronting a Health Crisis: Segmenting Patients to Optimize Treatment

Due to the increase in incidence of a particular disease worldwide, our client, a global pharmaceutical company, wanted to strengthen its future product portfolio to meet the needs of patients affected by this disease. The company partnered with Prescient to undertake a robust patient segmentation exercise to predict the level of need and the anticipated uptake within each segment of both marketed and pipeline products. The client also had a specific product in mind, so it was looking to understand the size of the opportunity represented by each segment.

Living Easier: Identifying Unmet Needs and Developing a TPP

Our client, a global pharmaceutical company, had a biologic in development for the treatment of a condition with a large uncontrolled population. It partnered with Prescient to both understand the target patient pool where product uptake would be the highest, and to optimize the target product profile (TPP) for commercial success.

Evolving Immunotherapy Strategies in NSCLC

Years of non-small cell lung cancer (NSCLC) research are beginning to result in significant gains in the standard of care, specifically for patients eligible for anti-PD-1 therapy. As all anti-PD-1s have the same pricing, the benefit of multiple approvals has not resulted in typical market behavior. The future challenge is to define the immunotherapy landscape and combination rationale, with a personalized, patient-centric approach.